• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于乙内酰脲、噻唑烷二酮和若丹宁的激酶抑制剂的构效关系研究与设计策略：二十年综述

Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review.

作者信息

Naufal Muhammad, Hermawati Elvira, Syah Yana Maolana, Hidayat Ace Tatang, Hidayat Ika Wiani, Al-Anshori Jamaludin

机构信息

Department of Chemistry, Padjadjaran University, Jalan Raya Bandung-Sumedang Km. 21, Jatinangor, Sumedang 45363, Indonesia.

Department of Chemistry, Bandung Institute of Technology, Jalan Ganesha Nomor 10, Bandung, Jawa Barat 40132, Indonesia.

出版信息

ACS Omega. 2024 Jan 19;9(4):4186-4209. doi: 10.1021/acsomega.3c04749. eCollection 2024 Jan 30.

DOI:10.1021/acsomega.3c04749
PMID:38313530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10832052/
Abstract

Cancer is one of the most prominent causes of the rapidly growing mortality numbers worldwide. Cancer originates from normal cells that have acquired the capability to alter their molecular, biochemical, and cellular traits. The alteration of cell signaling enzymes, such as kinases, can initiate and amplify cancer progression. As a curative method, the targeted therapy utilized small molecules' capability to inhibit kinase's cellular function. This review provides a brief history (1999-2023) of Small Molecule Kinase Inhibitors (SMKIs) discovery with their molecular perspective. Furthermore, this current review also addresses the application and the development of hydantoin, thiazolidinedione, and rhodanine-based derivatives as kinase inhibitors toward several subclasses (EGFR, PI3K, VEGFR, Pim, c-Met, CDK, IGFR, and ERK) accompanied by their structure-activity relationship study and their molecular interactions. The present work summarizes and compiles all the important structural information essential for developing hydantoin, thiazolidinedione, and rhodanine-based kinase inhibitors to improve their potency in the future.

摘要

癌症是全球死亡率迅速上升的最主要原因之一。癌症起源于正常细胞，这些细胞获得了改变其分子、生化和细胞特性的能力。细胞信号酶（如激酶）的改变可引发并加速癌症进展。作为一种治疗方法，靶向治疗利用小分子抑制激酶细胞功能的能力。本综述从分子角度简要介绍了小分子激酶抑制剂（SMKIs）的发现历史（1999 - 2023年）。此外，本综述还探讨了基于乙内酰脲、噻唑烷二酮和罗丹宁的衍生物作为激酶抑制剂在多个亚类（表皮生长因子受体、磷脂酰肌醇-3激酶、血管内皮生长因子受体、原癌基因激酶、肝细胞生长因子受体、细胞周期蛋白依赖性激酶、胰岛素样生长因子受体和细胞外信号调节激酶）中的应用和发展，并对其构效关系研究及其分子相互作用进行了阐述。本研究总结并汇编了开发基于乙内酰脲、噻唑烷二酮和罗丹宁的激酶抑制剂以提高其未来效力所需的所有重要结构信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/4bf0bfea26ca/ao3c04749_0043.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/f4979bff3d51/ao3c04749_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/2cbb07a73c99/ao3c04749_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/167d5a5e8aad/ao3c04749_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ffba8e3d824b/ao3c04749_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6c9805cc6830/ao3c04749_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/2079e15c54f2/ao3c04749_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c49da02999d6/ao3c04749_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/397049c0f163/ao3c04749_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/535b7bf4d1c4/ao3c04749_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/aac61bec3237/ao3c04749_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/050429fed870/ao3c04749_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b7ec963f2961/ao3c04749_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/f493a5b59d38/ao3c04749_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6f8c1acae07a/ao3c04749_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/aa01d232c612/ao3c04749_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/0e3dea6231c8/ao3c04749_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/563f329a643e/ao3c04749_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/94351c5f63a7/ao3c04749_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/eded7ac751be/ao3c04749_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/5e6d0a049255/ao3c04749_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/fa5692d3c961/ao3c04749_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c4a5840c675f/ao3c04749_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/caf1d0946ef2/ao3c04749_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b5426d44b023/ao3c04749_0024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6a90c1b7d0b3/ao3c04749_0025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ecc145b93968/ao3c04749_0026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c2aaa7c1d654/ao3c04749_0027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/43f5be360e5d/ao3c04749_0028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/8f78665b2fa4/ao3c04749_0029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/4a39b51e04bf/ao3c04749_0030.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ce350bf2fead/ao3c04749_0031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/0453c725ecb8/ao3c04749_0032.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/d0960e9bac94/ao3c04749_0033.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/fa1e4f5556c3/ao3c04749_0034.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/7ae4bc0a9b5c/ao3c04749_0035.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/a8e0a4d4d29a/ao3c04749_0036.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b1d00c449056/ao3c04749_0037.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/dbeefaa71695/ao3c04749_0038.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/052e786bf065/ao3c04749_0039.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/3abddc8b7d88/ao3c04749_0040.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c123cbbdff54/ao3c04749_0041.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c4d4dfe89bb7/ao3c04749_0042.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/4bf0bfea26ca/ao3c04749_0043.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/f4979bff3d51/ao3c04749_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/2cbb07a73c99/ao3c04749_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/167d5a5e8aad/ao3c04749_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ffba8e3d824b/ao3c04749_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6c9805cc6830/ao3c04749_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/2079e15c54f2/ao3c04749_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c49da02999d6/ao3c04749_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/397049c0f163/ao3c04749_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/535b7bf4d1c4/ao3c04749_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/aac61bec3237/ao3c04749_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/050429fed870/ao3c04749_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b7ec963f2961/ao3c04749_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/f493a5b59d38/ao3c04749_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6f8c1acae07a/ao3c04749_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/aa01d232c612/ao3c04749_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/0e3dea6231c8/ao3c04749_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/563f329a643e/ao3c04749_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/94351c5f63a7/ao3c04749_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/eded7ac751be/ao3c04749_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/5e6d0a049255/ao3c04749_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/fa5692d3c961/ao3c04749_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c4a5840c675f/ao3c04749_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/caf1d0946ef2/ao3c04749_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b5426d44b023/ao3c04749_0024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/6a90c1b7d0b3/ao3c04749_0025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ecc145b93968/ao3c04749_0026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c2aaa7c1d654/ao3c04749_0027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/43f5be360e5d/ao3c04749_0028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/8f78665b2fa4/ao3c04749_0029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/4a39b51e04bf/ao3c04749_0030.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/ce350bf2fead/ao3c04749_0031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/0453c725ecb8/ao3c04749_0032.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/d0960e9bac94/ao3c04749_0033.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/fa1e4f5556c3/ao3c04749_0034.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/7ae4bc0a9b5c/ao3c04749_0035.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/a8e0a4d4d29a/ao3c04749_0036.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/b1d00c449056/ao3c04749_0037.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/dbeefaa71695/ao3c04749_0038.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/052e786bf065/ao3c04749_0039.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/3abddc8b7d88/ao3c04749_0040.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c123cbbdff54/ao3c04749_0041.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/c4d4dfe89bb7/ao3c04749_0042.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5464/10832052/4bf0bfea26ca/ao3c04749_0043.jpg

相似文献

1
Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review.基于乙内酰脲、噻唑烷二酮和若丹宁的激酶抑制剂的构效关系研究与设计策略：二十年综述
ACS Omega. 2024 Jan 19;9(4):4186-4209. doi: 10.1021/acsomega.3c04749. eCollection 2024 Jan 30.
2
Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.具有罗丹宁-苯并咪唑结构的强效泛Pim激酶抑制剂的合理设计
Anticancer Res. 2017 Aug;37(8):4051-4057. doi: 10.21873/anticanres.11790.
3
Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.靶向 PIM 激酶以克服癌症中耐药性和免疫逃逸机制的最新观点。
Pharmacol Ther. 2020 Mar;207:107454. doi: 10.1016/j.pharmthera.2019.107454. Epub 2019 Dec 11.
4
Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.氨噻唑酮类作为有效、选择性和细胞活性的 PIM 激酶家族抑制剂。
Bioorg Med Chem. 2020 Nov 15;28(22):115724. doi: 10.1016/j.bmc.2020.115724. Epub 2020 Aug 26.
5
2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents.2H-色烯衍生物，具有噻唑烷-2,4-二酮、罗丹宁或海因环结构，作为有潜力的抗癌剂。
Eur J Med Chem. 2013 Jan;59:15-22. doi: 10.1016/j.ejmech.2012.10.044. Epub 2012 Nov 2.
6
Bacterial Cytological Profiling Identifies Rhodanine-Containing PAINS Analogs as Specific Inhibitors of Thymidylate Kinase .细菌细胞分析鉴定含有硫代氨基脲的类 PAINS 化合物为胸苷酸激酶的特异性抑制剂。
J Bacteriol. 2021 Sep 8;203(19):e0010521. doi: 10.1128/JB.00105-21.
7
How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors.吲哚衍生物的结构性质如何在激酶靶向药物设计中起重要作用？：以酪氨酸激酶抑制剂为例。
Bioorg Med Chem. 2022 Jan 1;53:116534. doi: 10.1016/j.bmc.2021.116534. Epub 2021 Nov 27.
8
Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities.具有咪唑并哒嗪和噻唑烷二酮结构的新型泛Pim激酶抑制剂具有强大的抗肿瘤活性。
Front Pharmacol. 2021 May 3;12:672536. doi: 10.3389/fphar.2021.672536. eCollection 2021.
9
Drug screening of rhodanine derivatives for antibacterial activity.拉罗丁衍生物的抗菌活性药物筛选。
Expert Opin Drug Discov. 2020 Feb;15(2):203-229. doi: 10.1080/17460441.2020.1696768. Epub 2019 Nov 28.
10
Green Synthesis, Biological Activity Evaluation, and Molecular Docking Studies of Aryl Alkylidene 2, 4-thiazolidinedione and Rhodanine Derivatives as Antimicrobial Agents.芳基亚烷基-2,4-噻唑烷二酮和若丹宁衍生物作为抗菌剂的绿色合成、生物活性评价及分子对接研究
Comb Chem High Throughput Screen. 2019;22(10):716-727. doi: 10.2174/1386207322666191127103122.

引用本文的文献

1
Isoniazid-rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation.异烟肼-若丹宁分子杂化物：设计、合成、抗分枝杆菌活性及计算验证
RSC Adv. 2025 Sep 1;15(38):31272-31288. doi: 10.1039/d5ra03641k. eCollection 2025 Aug 29.
2
‑Alkylated 5,5-Diphenylhydantoin Derivatives: Synthesis, X‑ray, Spectroscopic Characterization, Hirshfeld Surface Analysis, DFT, Molecular Docking, Molecular Dynamics Simulations, and Cholesterol Oxidase Binding Affinity Estimation.烷基化5,5-二苯基乙内酰脲衍生物：合成、X射线、光谱表征、 Hirshfeld表面分析、密度泛函理论、分子对接、分子动力学模拟及胆固醇氧化酶结合亲和力评估
ACS Omega. 2025 Jul 7;10(27):29267-29284. doi: 10.1021/acsomega.5c02215. eCollection 2025 Jul 15.
3

本文引用的文献

1
Rigid Scaffolds Are Promising for Designing Macrocyclic Kinase Inhibitors.刚性支架在设计大环激酶抑制剂方面颇具前景。
ACS Pharmacol Transl Sci. 2023 Jul 7;6(8):1182-1191. doi: 10.1021/acsptsci.3c00078. eCollection 2023 Aug 11.
2
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.DZD1516 的临床前和临床活性，DZD1516 是一种全血脑屏障穿透的、高选择性 HER2 抑制剂。
Breast Cancer Res. 2023 Jul 6;25(1):81. doi: 10.1186/s13058-023-01679-4.
3
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Identification of Furin Protease Small-Molecule Inhibitor with a 1,3-Thiazol-2-ylaminosulfonyl Scaffold.具有1,3-噻唑-2-基氨基磺酰基骨架的弗林蛋白酶小分子抑制剂的鉴定。
Pharmaceuticals (Basel). 2025 Feb 19;18(2):273. doi: 10.3390/ph18020273.
4
Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update).嘧啶：作为蛋白激酶抑制剂的抗癌药物开发的优势骨架（最新进展）
Curr Pharm Des. 2025;31(14):1100-1129. doi: 10.2174/0113816128346900241111115125.
5
Rapid and Environmentally-Friendly Synthesis of Thiazolidinone Analogues in Deep Eutectic Solvent Complemented with Computational Studies.在深共熔溶剂中快速且环保地合成噻唑烷酮类似物并辅以计算研究
ChemistryOpen. 2025 Feb;14(2):e202400198. doi: 10.1002/open.202400198. Epub 2024 Oct 25.
6
What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.为什么化疗药物在肺癌治疗中的药理前景可能与纳米结构最密切相关？铂类药物在非小细胞肺癌和小细胞肺癌治疗中的作用及其意想不到的可能相互作用。综述。
Int J Nanomedicine. 2024 Sep 14;19:9503-9547. doi: 10.2147/IJN.S469217. eCollection 2024.
7
Green synthesis, modeling, and biological evaluation of -substituted ()-5-arylidene imidazolidine/thiazolidine-2,4-dione/4-thione derivatives catalyzed by Bu SOH core-shell nanostructures.由Bu SOH核壳纳米结构催化的α-取代（）-5-亚芳基咪唑烷/噻唑烷-2,4-二酮/4-硫酮衍生物的绿色合成、建模及生物学评价
RSC Adv. 2024 Jul 19;14(32):22916-22938. doi: 10.1039/d4ra03881a.
呋喹替尼的发现：首个临床应用的共价FGFR激酶抑制剂
ACS Med Chem Lett. 2023 Mar 10;14(4):396-404. doi: 10.1021/acsmedchemlett.3c00006. eCollection 2023 Apr 13.
4
Pirtobrutinib: First Approval.泊鲁替尼：首次获批。
Drugs. 2023 Apr;83(6):547-553. doi: 10.1007/s40265-023-01860-1.
5
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.FDA 批准的小分子蛋白激酶抑制剂的特性：2023 年更新。
Pharmacol Res. 2023 Jan;187:106552. doi: 10.1016/j.phrs.2022.106552. Epub 2022 Nov 17.
6
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors.酪氨酸激酶抑制剂的代谢和毒性的最新进展。
Pharmacol Ther. 2022 Sep;237:108256. doi: 10.1016/j.pharmthera.2022.108256. Epub 2022 Jul 25.
7
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic.分子胶水：将靶向蛋白降解连接到临床的黏合剂。
Biochemistry. 2023 Feb 7;62(3):601-623. doi: 10.1021/acs.biochem.2c00245. Epub 2022 Jul 20.
8
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists.含磺酰基硫脲基团的噻唑烷-2,4-二酮类化合物作为有效的血管内皮生长因子受体-2（VEGFR-2）抑制剂和过氧化物酶体增殖物激活受体γ（PPARγ）激动剂的设计、分子对接、合成、抗癌及抗高血糖活性评估
Pharmaceuticals (Basel). 2022 Feb 14;15(2):226. doi: 10.3390/ph15020226.
9
A Primer on BRIMR: Understanding the Rankings of NIH Support from the Blue Ridge Institute for Medical Research.BRIMR入门：了解蓝岭医学研究所的国立卫生研究院资助排名
Am J Pathol. 2022 Mar;192(3):392-394. doi: 10.1016/j.ajpath.2021.12.004. Epub 2021 Dec 24.
10
Trends in kinase drug discovery: targets, indications and inhibitor design.激酶药物研发趋势：靶点、适应症和抑制剂设计。
Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5.